Cantor Fitzgerald Brokers Lower Earnings Estimates for SLNO

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for Soleno Therapeutics in a research note issued on Thursday, March 27th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($2.85) per share for the year, down from their previous forecast of ($2.65). Cantor Fitzgerald currently has a “Overweight” rating and a $123.00 target price on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share.

Other research analysts have also recently issued research reports about the company. Guggenheim reaffirmed a “buy” rating and issued a $81.00 price target (up previously from $70.00) on shares of Soleno Therapeutics in a report on Friday. Stifel Nicolaus lifted their target price on Soleno Therapeutics from $74.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, March 28th. Robert W. Baird upped their target price on Soleno Therapeutics from $72.00 to $102.00 and gave the company an “outperform” rating in a report on Thursday, March 27th. HC Wainwright lifted their price target on Soleno Therapeutics from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Laidlaw boosted their price objective on Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $98.86.

Soleno Therapeutics Price Performance

NASDAQ SLNO opened at $68.26 on Monday. The company has a market capitalization of $3.13 billion, a P/E ratio of -20.56 and a beta of -1.70. Soleno Therapeutics has a 12 month low of $36.61 and a 12 month high of $73.97. The company’s 50 day simple moving average is $49.82 and its 200 day simple moving average is $50.34.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, March 5th. The company reported ($1.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.41).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC raised its stake in shares of Soleno Therapeutics by 6,048,754.5% during the 3rd quarter. FMR LLC now owns 665,374 shares of the company’s stock worth $33,595,000 after purchasing an additional 665,363 shares in the last quarter. Barclays PLC increased its holdings in Soleno Therapeutics by 149.3% in the third quarter. Barclays PLC now owns 52,545 shares of the company’s stock worth $2,652,000 after buying an additional 31,467 shares during the last quarter. Emerald Advisers LLC raised its position in Soleno Therapeutics by 85.4% during the fourth quarter. Emerald Advisers LLC now owns 580,919 shares of the company’s stock valued at $26,112,000 after acquiring an additional 267,585 shares in the last quarter. State Street Corp lifted its stake in Soleno Therapeutics by 14.2% in the third quarter. State Street Corp now owns 1,142,169 shares of the company’s stock valued at $57,668,000 after acquiring an additional 142,033 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Soleno Therapeutics by 13.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 217,550 shares of the company’s stock worth $9,779,000 after acquiring an additional 24,953 shares in the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Insider Buying and Selling

In other news, CEO Bhatnagar Anish sold 10,937 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $45.41, for a total transaction of $496,649.17. Following the transaction, the chief executive officer now directly owns 708,616 shares in the company, valued at $32,178,252.56. The trade was a 1.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kristen Yen sold 2,340 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $46.18, for a total transaction of $108,061.20. Following the completion of the transaction, the insider now directly owns 76,605 shares in the company, valued at $3,537,618.90. This trade represents a 2.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 956,250 shares of company stock valued at $64,583,745. Corporate insiders own 12.30% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.